The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
Hepatitis C identification and care trends published in the December 2009 issue of Hepatology indicate a national, public health dilemma deserving of congressional action.
Continue reading »For populations who are less responsive to current licensed Hepatitis B vaccines, Dynavax is continuing its plans to resume development of HEPLISAV™ , the company's Phase 3 investigational Hepatitis B vaccine.
Continue reading »Menstruating women have to deal with a period every month, even when on interferon-ribavirin therapy for Hepatitis C. Although menstrual discomfort can be magnified by combination therapy's side effects, the usual drugs to relieve menstruation symptoms likely won't mix with antiviral therapy. Thankfully, there are some natural ways to help ease this additional challenge to completing treatment.
Continue reading »Despite the potentially severe side effects associated with Hepatitis C drugs, a new, long-awaited study reports that the two standard antiviral therapies are safe, best when started early in the disease process and help prevent liver damage.
Continue reading »Knowing which drugs contain acetaminophen can help you protect your liver and stay one step ahead of impending FDA legislation.
Continue reading »According to some investor analysts, Achillion's research and development programs (including potential Hep C solutions) make this company an ideal stock purchase.
Continue reading »By enrolling Hepatitis C patients for whom treatment with combination therapy is not advised, Conatus Pharmaceuticals is testing a unique compound that inhibits the activity of matrix metalloproteinases.
Continue reading »Ever since a Tennessee hospital disclosed that an internationally known businessman - Steve Jobs - recently received a liver transplant there, controversy has swirled around transplantation fairness.
Continue reading »At 2009's largest international gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery (Digestive Disease Week), substantial progress for those with liver disease, including chronic Hepatitis C, was presented.
Continue reading »Although their first attempt at Hepatitis C antiviral therapy was unsuccessful, a significant number of previous non-responders achieved a sustained viral response with once-daily Infergen with Ribavirin.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
